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Background: The pursuit of unproven stem cell-based interventions (“stem cell tourism”) is an emerging issue that
raises various concerns. Physicians play different roles in this market, many of which engage their legal, ethical and
professional obligations. In Canada, physicians are members of a self-regulated profession and their professional
regulatory bodies are responsible for regulating the practice of medicine and protecting the public interest. They
also provide policy guidance to their members and discipline members for unprofessional conduct.
Methods: We conducted semi-structured telephone interviews with representatives from six different provincial
Colleges of Physicians and Surgeons in Canada to discuss their experiences and perspectives regarding stem cell
tourism. Our focus was on exploring how different types of physician involvement in this market would be viewed
by physicians’ professional regulatory bodies in Canada.
Results: When considering physicians’ professional obligations, participants drew analogies between stem cell tourism
and other areas of medical tourism as well as with some aspects of complementary alternative medicine where
existing policies, codes of ethics and regulations provide some guidance. Canadian physicians are required to act in the
best interests of their patients, respect patient autonomy, avoid conflicts of interest and pursue evidence-based practice
in accordance with accepted standards of care. Physicians who provide unproven treatments falling outside the
standard of care, not in the context of an approved research protocol, could be subject to professional discipline.
Other types of problematic conduct include referrals involving financial conflict of interest and failure to provide
urgent medically necessary care. Areas of ambiguity include physicians’ obligations when asked for information
and advice about seeking unproven medical treatments, in terms of providing non-urgent follow-up care, and
when asked to support efforts to go abroad by providing tests or procedures in advance that would not otherwise be
medically indicated.
Conclusions: Specific policy guidance regarding the identified areas of tension or ambiguity may prove helpful for
physicians struggling with these issues. Further consideration of the complex interplay of factors at issue in how
physicians may (should) respond to patient demands related to unproven medical interventions while meeting their
professional, legal and ethical obligations, is warranted.
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The practice of medicine is unquestionably complex and
the challenges Canadian physicians and their counterparts
around the world face on a daily basis are numerous and
multi-faceted. Medical tourism – where patients deliber-
ately travel to receive medical care outside of their home
jurisdiction – is one such challenge. Medical tourism is far
from a new phenomenon and comes in many forms. In
Canada, as is true in other countries, some individuals
travel outside their home jurisdiction to pursue a wide
range of medical interventions, some of which are stand-
ard therapies (e.g. dental surgery, orthopedic surgery, etc.)
that may simply be more accessible (either financially or
in terms of wait times) in other jurisdictions. In other
cases, people travel to pursue treatment options that are
not available domestically for some reason such as legal
barriers (e.g., commercial surrogacy) or insufficient evi-
dence of safety and/or efficacy (e.g., liberation therapy to
treat chronic cerebrospinal insufficiency venous syndrome
(CCSVI)) [1].
One particular type of medical tourism receiving in-
creasing attention is the pursuit of unproven stem cell-
based interventions, often referred to as “stem cell
tourism” [2]. Private clinics around the world are adver-
tising unproven stem cell-based interventions on a
direct-to-consumer basis over the internet. These treat-
ments are offered for a wide range of conditions, in-
cluding autism, ALS, spinal cord injury and multiple
sclerosis, among many others [3-5]. Although evidence
on the veracity of the claims made on clinic websites,
on patient blogs and in newspaper reports is lacking,
various cell sources are purportedly used including (but
not limited to) adult autologous, fetal, umbilical cord and
embryonic [6]. Patients typically pay for these treatments
out-of-pocket and, although robust data is lacking, news-
paper coverage reflects an average cost of approximately
$47,315.00 USD [7]. The primary concern associated with
this emerging market is risk to participating individuals.
Reported adverse consequences include meningitis [8],
tumours [9], other lesions [10], and death [11]. The long-
term risks of currently unidentified or unanticipated ad-
verse consequences also should not be underestimated.
Although we have adopted the term “stem cell tourism”
for the purpose of this study because it has been widely
used in previous research in the area, we do so in recogni-
tion of several important caveats. First, we recognize the
concern that the use of “tourism” may be seen to minimize
the incredibly difficult realities many individuals involved
are dealing with [12], and in no way suggest these pursuits
are undertaken lightly or without significant hardship. The
term may also be misleading if it is taken to mean that
travel is necessarily involved. In the early stages of the de-
veloping international market for unproven stem cell-
based interventions, concerns tended to focus on patientstravelling from Western countries to clinics operating in
countries with less stringent regulatory regimes [3-5].
However, increasingly the debate is turning to more
tightly regulated countries such as the United States and
Australia and the emerging practice of autologous stem
cell treatments [13]. These developments are serving to
heighten debates surrounding physicians’ conduct in pro-
viding autologous stem cell-based interventions that have
not been proven safe or effective by traditional means and
makes the research presented here particularly timely.
This emerging practice also highlights a key point for dis-
course and policy work addressing the stem cell tourism
market – the location of the intervention is not of central
importance; its unproven nature however is.
Physicians play various roles in the stem cell tourism
market. For example, in some cases they provide un-
proven stem cell-based interventions directly to their pa-
tients [14,15]; in other cases they advertise or offer
referrals to providers in other jurisdictions [16]. In yet
other situations they act as sources of information and
advice for their patients [17,18], among various other
types and degrees of involvement (e.g., clinic ownership,
membership on advisory boards, suppliers of cell lines,
etc.). Even when physicians are not directly involved in
providing the unproven interventions, research from other
areas of medical tourism suggests that physicians are
being asked by patients for advice and direction about
procedures offered elsewhere [19], and are also being
approached by patients seeking medical records or par-
ticular diagnostic tests to prepare for treatment abroad
[20]. They may further be asked to provide follow-up
care upon a patient’s return from receiving unproven
treatment elsewhere – as was the case with Canadian
multiple sclerosis patients returning from having had lib-
eration therapy for CCSVI outside the country [21,22].
Each of these circumstances raises different potential is-
sues for the physician involved from ethical, legal and
practical perspectives.
In Canada, as is true in other jurisdictions around the
world, medicine is a self-regulated profession. All ten
provinces in the country have a College of Physicians and
Surgeons that is empowered by provincial legislation to
regulate the practice of medicine in that province and the
three territories operate on a similar basis (Table 1). The
Colleges are typically responsible for licensing physicians,
maintaining standards of practice, investigating com-
plaints and disciplining members. They are also generally
required to act in the public interest and/or to protect the
public (e.g., Medical Profession Act, 1981, s. 69.1) [23]. Ac-
cordingly, these medical regulatory authorities have a vital
role to play in the oversight of members’ conduct includ-
ing in relation to their involvement in or experience with
stem cell tourism and other forms of medical tourism. In
this paper, we explore how medical regulatory authorities
Table 1 Overview of medical self-regulation in Canada
Province/Territory Medical Regulatory Authority Empowering Legislation
British Columbia College of Physicians and Surgeons of British Columbia Health Professions Act, R.S.B.C. 1996, c. 183
Alberta College of Physicians and Surgeons of Alberta Health Professions Act, R.S.A. 2000, c. H-7
Saskatchewan College of Physicians and Surgeons of Saskatchewan The Medical Profession Act, 1981, S.S. 1980–81, c. M-10.1
Manitoba College of Physicians and Surgeons of Manitoba The Medical Act, C.C.S.M. 2009, c. M90
Ontario College of Physicians and Surgeons of Ontario Regulated Health Professions Act, S.O. 1991, c. 18
Medicine Act, S.O. 1991, c. 30
Quebec Collège des médecins du Quebec/College of Physicians
and Surgeons of Quebec
Medical Act, R.S.Q. 1973, c. M-9
Nova Scotia College of Physicians and Surgeons of Nova Scotia Medical Act, S.N.S. 1995–6, c. 10
Prince Edward Island College of Physicians and Surgeons of Prince Edward Island Medical Act, RSPEI 1988, c. M-5
New Brunswick College of Physicians and Surgeons of New Brunswick Medical Act, S.N.B. 1981
Newfoundland and Labrador College of Physicians and Surgeons of Newfoundland
and Labrador
Medical Act, SNL 2011, M-4.02
Yukon Yukon Medical Council Medical Profession Act, R.S.Y, 2000, c. 149
Northwest Territories Department of Health and Social Services Medical Profession Act, S.N.W.T. 2010, c.6
Nunavut Department of Health and Social Services Medical Profession Act, R.S.N.W.T. 1988, c. M-9
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with a view to clarifying physicians’ professional responsi-
bilities in this and related contexts. The legal and profes-
sional obligations physicians have when encountering
unproven stem cell-based interventions is a topic that has
received some consideration [17], and which merits fur-
ther enquiry given the complexities and concerns sur-
rounding this emerging area of medical tourism.
Methods
We conducted a qualitative study based on semi-structured
interviews with representatives from Colleges of Physicians
and Surgeons in Canada. All of our participants were in
leadership and/or senior administrative positions with
knowledge of both policy and disciplinary activities of their
College. Some had medical backgrounds, but all spoke from
the perspective of a representative of their College, as
opposed to that of a practicing physician. The aim of these
interviews was to gain insight into their experiences and
perspectives in relation to stem cell tourism, in order to
understand how different kinds of physician involvement in
stem cell tourism might be dealt with by professional self-
regulatory authorities in Canada. This research was ap-
proved in advance by the Research Ethics Boards at the
University of Regina and the University of Alberta. All par-
ticipants provided informed consent before taking part in
this study.
Recruitment
Letters of invitation were sent by email to the Registrar of
each College of Physicians and Surgeons in Canada (and
their counterparts in the territories), using contact infor-
mation provided on their public websites. Invitations wereaccompanied by information about the research project
and a consent form. Responses were received from
eight Colleges. Two of those eight declined to partici-
pate, citing lack of familiarity and/or experience with the
area, and six agreed. Recruitment efforts ceased after one
round of follow-up emails sent to unresponsive invitees.
Semi-structured interviews were conducted by telephone
between September, 2013 and January, 2014. All inter-
views were conducted by the same investigator (AZ) to
promote consistency.
Data collection
A semi-structured interview approach [24] was adopted
to ensure key areas of enquiry could be addressed while
leaving considerable room and flexibility for participants
to raise unanticipated issues and topics. In advance of
the interviews, participants were provided with an intro-
duction to stem cell tourism (Appendix A) as well as
three short case studies (Appendix B), each based on an
actual instance of physician involvement in stem cell
tourism. The cases were used to provide examples and
context to the questions posed during the interviews.
The interviews canvassed a variety of different areas
including physician referrals to treatment providers lo-
cated in other jurisdictions, physicians actually providing
unproven interventions, physicians providing follow-up
care to patients upon their return from receiving treat-
ment elsewhere, physicians providing information and
advice to patients asking about stem cell-based interven-
tions available in other jurisdictions, and reach of the
regulatory jurisdiction or authority of the Colleges over
their members. Broadly, we were interested in learning
whether the Colleges had any experience with stem cell
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ticipated different kinds of situations would be viewed or
dealt with under their existing regulatory regime. To
that end, different examples (emerging from the case
studies) were put to the participants and they were asked
for their reactions, including how they would anticipate
such a case being dealt with if it involved a doctor
licensed by their College.
Analysis
Interviews generally ran from between thirty to sixty
minutes. They were digitally recorded and later tran-
scribed verbatim. Both investigators reviewed all tran-
scripts and notes independently to identify emerging
themes relevant to the overarching research objectives.
These themes were compared and discussed by both in-
vestigators and a preliminary coding scheme that cap-
tured the major topics in the data was developed [24].
This coding scheme consisted of a ‘long list’ of initial
themes.
The second author then coded the data by placing
relevant phrases and sentences from the transcripts into
these thematic categories. The coded data was subject to
further review and iterative analysis by both authors. Au-
thors engaged in frequent conversation to further refine
and interpret these themes. Ultimately, five overarching
themes were agreed upon that addressed the research
objectives and captured ideas identified deductively in
the transcripts [25].
Results
A number of clear themes emerged. There were interest-
ing points of agreement upon which participants were
fairly consistent in their conclusions regarding the utility
of existing guiding principles. There were also a number
of areas where the discussions reflected various ambigu-
ities and tensions.
Drawing on existing frameworks
Although only one participant had dealt directly with
stem cell tourism, all participants recognized familiar
issues raised by this practice. In anticipating how their
College might respond to different kinds of circum-
stances in the stem cell tourism arena, including those
presented in the case studies, many drew analogies with
other topics with which they were more familiar. These
analogies often related to other areas of medical tour-
ism and, in a couple of cases, complementary alterna-
tive medicine.
Participants generally agreed that both medical tour-
ism and complementary alternative medicine - and, by
extension, stem cell tourism - raise a number of issues
from a regulatory perspective, some of which can be
addressed in a fairly straightforward manner underestablished principles (discussed more below), while
others present greater challenges. Almost all partici-
pants made specific reference to the controversies that
emerged surrounding CCSVI and drew analogies be-
tween the challenges Canadian physicians and Colleges
experienced in relation to that phenomenon, and what
might be anticipated to occur in the context of stem
cell tourism. Although medical tourism was not found
to be an exceptionally persistent concern for Colleges
in Canada at the moment, participants recognized the po-
tential for increasingly complicated scenarios to emerge as
it becomes more commonplace.
Where the lines are (somewhat) clear: conflict of interest,
the rules for research and evidence-based practice
There was consensus among participants that conflicts
of interest are a source of significant concern for the
Colleges. For example, participants were in agreement
that referrals to clinics or treatment providers with
which a physician has a financial relationship (e.g., off-
shore clinics owned in whole or part by the Canadian
physician or from which the Canadian physician receives
a referral fee) would in most cases constitute an un-
acceptable conflict of interest. As one participant noted:
“Physicians … are precluded from getting any financial
benefit from [referral] activity” (P1). Another elaborated:
“The physician’s interest should never be put before pa-
tient interest…there shouldn’t be a financial benefit
strictly for a referral. Referrals are an important part of
care” (P2). Another stated: “Well I think it is all kind of
shades of grey but the worst is when the physician is part
of the ownership of the clinic. That would be the most
egregious and you know, just because to do that work in
Canada would be illegal, unethical and unprofessional
doesn’t make it right if you then refer people [for that
same treatment] outside of our jurisdiction. So we would
take a dim view of that” (P3).
Participants also agreed that when looking at treat-
ment provided by a physician, a central question from a
regulatory perspective is whether the treatment meets
the standard of care and has an appropriate evidentiary
foundation. As one participant noted, “generally speak-
ing a very key foundational element is that physicians
shouldn’t be doing things that are not approved” (P2).
For example, as noted above some physicians in jurisdic-
tions such as the United States are apparently providing
adult autologous stem cell treatments for orthopedic in-
juries (potentially among other indications). A debate has
emerged in the United States regarding whether this prac-
tice should or should not fall under the regulatory author-
ity of the FDA [26,27] and whether it may in fact violate
physicians’ professional and ethical duties [28].
Our participants generally expressed that if an inter-
vention provided falls outside the approved standard of
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be determined whether the physician is engaging in re-
search. If so, participants identified existing research
ethics and clinical trial approval processes which gov-
ern research behaviour and expressed that physicians
should not engage in research involving patients outside
of these frameworks. In some cases, clinical research may
present options for individuals who have encountered the
limits of conventional treatment. However, human sub-
jects research is subject to and guided by clearly defined
rules and processes, including requirements for informed
consent and an appropriate risk-benefit assessment. Par-
ticipants agreed that any physician referring or providing
experimental treatment or unproven procedures would
generally be required to do so in the context of approved
clinical research. As one physician stated: “Non-standard
therapy can only be provided when it is part of an appro-
priately constituted research ethics board approved trial”
(P3).
Some participants also noted the importance of in-
formed consent in this context – i.e. when treatment is
proposed that falls outside conventional therapy – and
reflected on the importance of a robust risk/benefit ana-
lysis. Participants did not engage in detailed discussion of
medical innovation in this context, beyond comments rec-
ognizing the speed with which emerging fields of science
can move – discussed further below.
Managing expectations: where clarity erodes
The utility of existing regulatory frameworks to guide
the conduct of physicians only extended so far. Partici-
pants described several examples of physicians’ indirect
involvement in medical tourism generally, or stem cell
tourism in particular, where the line between appropriate
and inappropriate conduct was less clear. These exam-
ples often related in one way or another to the manage-
ment of patients’ expectations.
One area several participants struggled with (or dif-
fered from one another on) was the extent to which phy-
sicians are or are not obligated to be (or become)
informed about novel or unproven interventions. One
scenario familiar to several participants was that of hav-
ing a patient ask his/her doctor for additional informa-
tion or advice regarding a treatment he/she had heard
about elsewhere – often via information obtained on the
internet. For example, one participant shared the follow-
ing thoughts:
“In years past they didn’t have the Internet, they
would have some access, support groups and a few
other things, but they wouldn’t have 500 sheets that
they just printed off this morning which they want you
to read, and doctors do express some frustration with
that… There is nothing that comes back without asearch in Google but patients are not really in a
position to separate the wheat from the chaff” (P1).
Another participant explained the College’s process in
responding to related queries:
“We do sometimes get inquiries from physicians to
say well what kind of role do I play if my patient
tells me that they want to go out of province or out of
country or something and our normal advice is, well,
you provide them the same guidance you provide
them any other time. If you have an opinion with
respect to the medical decision that they are going to
undertake, then you try to provide as much balanced
information as possible so that they can make the
best decision for themselves” (P4).
There was general recognition of the challenges physi-
cians face in these contexts and the very real limitations
that exist in terms of physicians’ knowledge, expertise and
available time. In other words, participants who discussed
this issue were fairly united in the view that physicians
simply cannot be expected to know everything about all
cutting-edge research possibilities or about every therapy/
intervention available on the private market – particularly
in other countries. As one participant stated: “I don’t think
I would expect a physician to be fully aware of what hap-
pens in Costa Rica. I mean there is a limit as to the expec-
tations that a physician should be knowledgeable about”
(P3).
Participants differed somewhat in terms of how far they
would expect a physician to go to become informed. Some
expressed that it would be fine for a physician to simply
say he/she did not know: “Physicians must tell patients
what information they have. If they know something
about something they should mention it. They have a
right to inform their patients. They would also be re-
sponsible for informing patients if they don’t know what
it is all about and if they are dubious or don’t have any
information on whether it is a safe or successful ther-
apy” (P5). Others felt physicians may have some obliga-
tion to at least refer the patient to a more knowledgeable
source of information. For example, one participant sug-
gested that in some circumstances,
“I think they would perhaps be expected to pick up
the phone and particularly a family doctor who has
got an ongoing continuity of care relationship with a
patient who kind of co-manages them with say a
cancer agency or the MS clinic or an orthopedic sur-
geon, to at least discuss it with the consulting doctor
so they have that doctor to doctor conversation; but
it may be ‘I am sorry I have looked into this. This is
not standard therapy; I can’t really assist you in
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beyond what we do’” (P3).
In the words of another participant: “they should con-
sider whether they can assist patients in obtaining infor-
mation and it might involve suggesting resources to the
patients or referring patients to other practitioners if it is
in the patients’ best interest and will support their pos-
ition. So there is no strong obligation to know about
things. It is more of think about whether you can help
your patient” (P2). Some participants distinguished be-
tween specialists and general practitioners, to the extent
that the onus may be stronger on specialists to be
abreast of emerging developments (including current re-
search) in their field.
Another issue participants identified as being poten-
tially problematic related to physicians being asked by
patients to provide pre-procedure testing and/or post-
treatment follow-up care. Indeed, this was the area some
participants identified as having had the most experience
with in the medical tourism context. One participant
expressed the following: “The majority of the calls we get
are more related to when something goes wrong and
these patients have come back into the system - what re-
sponsibility do physicians, say in the emergency depart-
ments or some specialists like plastic surgeons, have
when they are called to see a patient who has received
treatment from a treating physician outside the country?”
(P4).
A number of participants identified these situations as
having emerged as areas of concern in the context of the
CCSVI phenomenon in Canada. When it came to the
question of pre- procedure testing, a central question
from a professional regulatory perspective was whether
the test would have been ordered in any event. One par-
ticipant suggested the College would provide the follow-
ing advice to a physician wondering how to deal with a
request for pre-procedure testing: “if you don’t think this
is useful then you are under no obligation to do so and
we would question why you would do so” (P6).
In terms of providing post-treatment care, participants
often distinguished between emergent care needs and
procedure-specific follow-up. An example given was
when Canadian physicians were asked to provide follow-
up ultrasounds for patients who received liberation
therapy to treat CCSVI out of the country. These situa-
tions can be contrasted to when patients who received
the same therapy experienced blood clots or other
medical crises upon return. One participant provided
the following context:
“We needed to remind people that just because they
went and got an experimental procedure that the
doctor didn’t agree with didn’t mean that the doctorcould provide no care. They were certainly not
ethically obliged to provide follow-up imaging or re-
peat the procedure which had been done somewhere
else, but they did need to be alive to urgent emergent
situations that might be a consequence of that therapy,
such as a stent that had moved, or infection or a
complete blood clot or something like that obviously
would require urgent emergent care” (P3).
Participants generally agreed that overall, physicians
were obliged to provide emergent care in accordance
with existing standards of care and regulatory frame-
works. One suggested the following: “the code of ethics
addresses the circumstances for which you can provide
care to a patient, [and] the circumstances in which you
could deny or refuse to provide care to a patient” (P4).
Others echoed this sentiment and suggested that physi-
cians are ethically required to treat patients regardless
of whether they agree with their decisions (i.e. to pur-
sue treatment elsewhere) or not. One stressed that phy-
sicians should not base their care decisions on an
ethical or valued appraisal of a patient’s decision. Hav-
ing said that, a number of participants also acknowl-
edged the difficulties their members encounter when
asked to provide follow-up care for a procedure that
falls outside the current standard of care, often in the
absence of adequate information, and when the re-
quested intervention would not otherwise be medically
indicated.
The physician-patient relationship: a balancing act
The idea that physician conduct should be guided by
the patient’s best interests was stressed repeatedly by
participants. However, there was also widespread recog-
nition that in practice, determining the appropriate
course of action in situations where patients want to
pursue an unproven treatment, potentially outside their
home jurisdiction, can be a challenge. Participants ex-
plained that physicians are often trying to balance re-
spect for patient autonomy, the need and desire to act
in their patients’ best interests, and the duty to meet
the standard of care – and, in cases of medical tourism
or complementary alternative medicine, often with im-
perfect information.
As one participant noted,
“[Physicians] understand the desperation the patient
feels. I mean the basic rules are you always have to
consider the wellbeing of the patient; you should never
do anything that you don’t think is in the patient’s best
interests. But, at the same time you have to respect the
patient’s right to accept or reject any medical
treatment and, as I said, there has also been a long
standing rule that they are to respect the patient’s
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choice”(P1).
Discussions of patient autonomy were often linked to
the importance of informed consent. For example, one
participant noted the following:
“we have a regulatory framework; we are looking at
this from the perspective of the patient and that sort of
push and pull between a patient being entitled to
make an autonomous decision even if it is one that
may not in the eyes of other people look like a good
one. Patients are entitled to do so but fundamental to
that is - does this patient know what he or she is fight-
ing, have they been provided with enough information
to know what they are getting into, how has the doctor
represented the treatment?” (P2).
Of course, one of the recognized challenges when an
individual pursues care elsewhere is that his/her doctor
in Canada will often have few to no details regarding
(and certainly no control over) what information the in-
dividual may or may not have received about the par-
ticular intervention and its attendant risks.
A related tension acknowledged in various ways by dif-
ferent participants was the concern physicians may feel
about damaging the doctor-patient relationship such
that future care may be compromised. For example, one
participant reflected on experience with physicians who
have been asked for an opinion about an unproven treat-
ment and who fear that providing a critical perspective
may not dissuade the patient but rather make them re-
luctant to return to him/her for necessary care after-
wards, thereby damaging continuity of care (and perhaps
exposing the patient to additional risk). “It would prob-
ably be more a situation of discussion and advice as op-
posed to saying ‘no you cannot do this’ because in some
cases the physician worries about affecting the doctor/pa-
tient relationship by refusing to order the test and so they
make a decision that overall it is not a bad thing” (P6).
Another participant noted: “certainly the trusting rela-
tionship between the doctors and patients is something
we are very, very much alive to in terms of the policy
work that we do” (P2). Indeed, the importance of the
doctor-patient relationship emerged at various points
throughout the interviews with recognition given to the
concern physicians may feel about damaging it.
Moving forward: challenges and opportunities
While participants acknowledged various challenges their
members currently face in relation to different aspects of
medical tourism, it seems unlikely we will see any signifi-
cant policy focus on this area any time soon, absent a
fairly dramatic rise in associated complaints or calls forguidance from physicians. The general approach to ad-
dressing medical tourism from a regulatory perspective in
Canada is currently more reactive than proactive, perhaps
because the Colleges are not encountering issues and con-
troversies related to medical tourism frequently or dra-
matically enough to merit action. As one participant put
it: “We can’t be everything to all people all the time and so
you tend to focus your policy initiatives in those areas
where there appears to be an issue of concern” (P6). Partic-
ipants also indicated that regulation should be guided by
the desire to ensure quality of care and not necessarily to
‘police’ conduct; in some cases we heard a mild caution
not to engage in regulation for the sake of regulation.
Another participant expressed: “there is a limit to what we
can do as regulators” (P3).
In addition to these practical and principle-based fac-
tors, participants also identified a number of challenges
that may preclude or deter proactive efforts in the area
of stem cell tourism. The ever changing and expanding
boundaries of globalized health care were one such fac-
tor; another related to the limits not only of physicians’
knowledge as individuals, but the knowledge of the field,
in that there is a continuously shifting and precarious
line drawn between standard of care and innovation, be-
tween evidence and hope. As one participant said, “what
might be experimental treatment now could be standard
care in two years” (P3). This line of thought seems par-
ticularly relevant in the context of the debates refer-
enced earlier regarding the administration of autologous
stem cell-based interventions.
Interestingly, the long reach of the regulatory arm
emerged as a significant strength in the ability of pro-
fessional regulation to oversee and address problematic
conduct on the part of physicians, as did its focus on
protecting the interests of patients and the public. Al-
though participants varied somewhat in their levels of
conviction, all acknowledged that their College would
certainly take an interest in the conduct of their mem-
bers even where it took place outside their jurisdiction.
Some went on to confirm that their physicians are sub-
ject to their rules, policies, and disciplinary processes,
wherever they provide care. And all were very much
alive to the responsibility self-regulated professions
have to protect the public interest.
Discussion
As members of a self-regulated profession, Canadian
physicians are governed and guided by their respective
professional regulatory body which, at the provincial
level, is the relevant College of Physicians and Surgeons.
As outlined above, in this research we interviewed repre-
sentatives from six provincial Colleges of Physicians and
Surgeons in Canada to investigate their perspectives on
stem cell tourism and how different types of physician
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of themes emerged from these discussions, centering on
both areas of clarity and ambiguity, and many of these
echo previous research on related areas of medical tour-
ism. It was perhaps no surprise that in general our par-
ticipants expressed that many of the issues raised by
stem cell tourism are not specific to this area and that
there are existing guidelines, regulations and policies
that would apply to some of the challenges the area
shares with analogous issues [29-31] .
Nonetheless, it is also apparent that guidelines, regula-
tions and policy can only go so far and the specific facts
at hand in a particular case are always of central import-
ance. The nature of the doctor-patient relationship at
issue, the apparent motivations of the physician and the
specific circumstances of the patient all play a role in
how complaints are evaluated. While this reality is argu-
ably one of the benefits of the professional disciplinary
process, it must also be noted that it carries some chal-
lenge for meaningful prospective policy guidance. As one
of our participants noted a number of times throughout
our discussion, many of these questions and their answers
fall in “shades of grey”. Indeed, the complexities and nu-
ances engaged in determining what may or may not be
unprofessional conduct on the part of physicians in the
types of circumstances addressed in this research should
not be underestimated. Unfortunately, this reality may
leave a number of important questions unanswered when
it comes to providing support for busy physicians seeking
to respond in real-time to the needs and requests of their
patients.
It was clear from all participants that Canadian physi-
cians are required to act in the best interests of their pa-
tients, to respect patient autonomy, ensure appropriately
informed consent, avoid conflicts of interest and pursue
evidence-based practice in accordance with accepted
standards of care. Although these basic principles are
laudable and seemingly straightforward, it remains to be
seen how they will be applied and interpreted if and
when the provision of unproven stem cell-based inter-
ventions comes closer to home. To-date, we in Canada
are not yet seeing the same rise in adult autologous stem
cell transfers as are our American neighbours. When
asked about this practice, the majority of our participants
turned their focus to two key questions – first, whether
there is evidence to support the treatment, and second, if
not, whether it is being provided in the context of an ap-
proved research protocol. As noted above, some also
highlighted the importance of informed consent in this
context, the role of evidence and scientific rationale for
treatment protocols, and of ensuring an appropriate risk/
benefit ratio. However, it is yet to be determined how the
Colleges would respond if Canadian physicians were to
enter this market by routinely providing autologous stemcell-based interventions. It also remains to be seen how
this practice would relate to law and policy surrounding
medical innovation, compassionate access and ‘right to
try’ movements, among other issues. It is beyond the
scope of this paper to engage in such an analysis here, but
further study on these questions is merited.
Other types of conduct Canadian Colleges of Physi-
cians and Surgeons are likely to take a dim view of in-
clude referrals where a physician has a financial interest
and failure to provide urgent medically necessary care,
regardless of the reason for the immediate medical need.
It is also evident there are areas of tension that are not
answered decisively by current regimes and where
Canadian physicians’ obligations are less clear from a
regulatory perspective. These areas of greater ambiguity
relate primarily to less direct forms of physician involve-
ment in stem cell tourism, including how far physicians
are required to go when asked for information and ad-
vice about seeking medical treatment (including a stem
cell-based intervention) outside the jurisdiction, what
their obligations are in terms of providing non-urgent
follow-up care, and to what extent they can/should/
should not support efforts to pursue care elsewhere by
providing tests or procedures that would not otherwise
be medically indicated.
These tensions have been identified in other research
on medical tourism [32,19], along with concerns that
physicians may fear negative impacts on their relation-
ships with their patients (which may threaten continuity
of care) if they refuse requests for pre-procedure testing
[19], and questions regarding the implications of having
minor patients – or others lacking decision-making cap-
acity – involved [33]. These concerns, echoed by a num-
ber of our participants, are also areas that arguably have
the greatest implications for the health care system as a
whole, in that they involve the expenditure of public
health care dollars and engage the role of the state in
supporting and at times protecting the health of its citi-
zens. The empirical data presented in this research sup-
ports previously identified needs for greater clarity and
guidance to be made available to physicians who are
grappling with these issues in their daily practices.
Limitations
We did not interview representatives from every provin-
cial or territorial medical regulatory body in Canada so
these data cannot be considered comprehensive. The in-
terviews reflect the perspectives of individual partici-
pants in leadership roles but also cannot necessarily be
interpreted as reflecting the views of everyone involved
in the regulatory process or in a given College. None-
theless, these results present useful insight into how
different kinds of physician involvement in the stem
cell tourism market would likely be viewed by medical
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areas where future policy development may be most im-
portant. Given similarities in general principles of profes-
sional regulation, these insights may also be broadly
applicable to other jurisdictions with comparable profes-
sional regulatory regimes for physicians.
Conclusions
It is the areas of tension or ambiguity identified in this
research where future policy work in the form of guid-
ance from medical regulators to their members may
ultimately prove particularly useful. As professional self-
regulatory bodies, Canadian Colleges of Physicians and
Surgeons have significant power and authority over the
medical profession. They also are a tremendous resource
to their members when it comes to providing advice and
guidance in relation to challenging areas of practice. In
the absence of specific guidance produced by their
College, these data indicate that at present Canadian
physicians should look to existing codes of ethics, stan-
dards of practice, regulations and policies to guide their
conduct in circumstances where they may feel conflicted
or challenged by issues associated with stem cell tourism
and arguably, other areas of medical tourism.
Future research examining the extent to which physi-
cians are aware of and act in accordance with these frame-
works would be valuable. If medical tourism in general
continues to grow in Canada, and if stem cell tourism in
particular becomes an issue more Canadian physicians are
faced with on a routine basis, the Colleges may be called
upon to provide more direct advice or guidance to their
members regarding how to deal with the areas of tension
identified above. Should that occur, it appears from these
interviews that they will be well-placed to do so given the
wealth of existing principles and guidance they have to
drawn upon. These are important issues for patients,
healthcare providers and health policy leaders, and as glo-
bal health markets continue to develop it is essential these
conversations continue.
Appendix A
Background information provided to participants
Stem cell tourism is the phrase commonly used to de-
scribe the phenomenon whereby individuals pursue stem
cell-based interventions that have not been proven to be
safe, effective or ready for routine clinical use. Clinics
around the world offer these stem cell-based interven-
tions to treat innumerable conditions ranging from
autism to ALS, heart disease to spinal cord injury, mul-
tiple sclerosis to aging, often at great expense to the
individual patient. These services are generally marketed
online, on a direct-to-consumer basis. In many cases, pa-
tients travel (hence the inclusion of “tourism” in the de-
scription) to pursue these interventions in jurisdictionsthat historically have had less stringent regulation in this
area (e.g., China, India and Mexico). However, increas-
ingly these transactions are also being reported in juris-
dictions with well-established regulatory controls for
scientific research and development, such as the U.S. Con-
cerns associated with stem cell tourism are numerous and
include risks to participants’ health, questions regarding
the accuracy of the information communicated to pro-
spective patients (i.e. how the treatments are portrayed
and the degree to which risks and unknowns are ex-
plained), the financial strain associated with high treat-
ment costs and travel expenses and threats to the
legitimacy of and long-term support for the stem cell re-
search field.
Appendix B
Case studies presented to participants
Case Study A: Dr. T, UK
Dr. T was brought before the United Kingdom’s General
Medical Council (GMC) to assess his fitness to practise,
following accusations of misconduct with regard to stem
cell-based treatments for multiple sclerosis he provided
both in England and in the Netherlands. In a number of in-
stances, he met with the patient first in London but subse-
quently provided treatment at his clinic in the Netherlands.
The Fitness to Practice Panel determined that Dr. T’s fit-
ness to practise was impaired by reason of his misconduct.
Dr. T’s actions constituted “repeated and serious breaches
of many of the essential tenets of ‘Good Medical Practice’”.
The Panel’s findings included the following: Dr. T failed to
respect the rights of the patient to be fully informed; he
abused his position as a doctor; his treatment lacked the
rigour required for a medical practitioner to embark on
pioneering treatment, including lack of physical assessment
pre-and post-treatment, lack of expertise in the research
area and lack of follow-up consultation or care. The Panel
directed Dr. T’s name be erased from the Medical Register,
noting that UK physicians are bound by the standards re-
quired by the GMC despite carrying out their duties out-
side of this jurisdiction.
Case Study B: Dr. W, Singapore
Dr. W was registered as an obstetrics and gynaecology
physician in Singapore when he was convicted of profes-
sional misconduct for advertising a service in which he
would provide pre-and post-treatment care and accom-
pany patients to foreign clinics where they would receive
stem cell therapy for facial and body rejuvenation. The
disciplinary committee found the location of these treat-
ments was irrelevant and he should have known the
treatments were not medically proven and therefore pro-
hibited. The resulting sanction included a $10,000 fine
(in addition to the costs of the hearing), censure, and a
written agreement to refrain from these activities.
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Dr. P was an orthopedic surgeon who injected his patient
with autologous stem cells (fat and bone marrow cells) to
treat ligament damage to his elbow and shoulder. The pa-
tient reportedly recovered from the injuries and was very
satisfied with the treatment provided.
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